Publication:
IS SECOND LINE SYSTEMIC CHEMOTHERAPY BENEFICIAL IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC)? : A MULTICENTER DATA EVALUATION OF ANATOLIAN SOCIETY OF MEDICAL ONCOLOGY (ASMO)

Simple item page
dc.contributor.authorsOdabas, Hatice; Ulas, Arife; Aydin, Kubra; Inanc, Mevlude; Aksoy, Asude; Yazilitas, Dogan; Turkeli, Mehmet; Yuksel, Sinemis; Inal, Ali; Ekinci, Ahmet S.; Sevinc, Alper; Demirci, Nebi S.; Uysal, Mukremin; Alkis, Necati; Dane, Faysal; Gumus, Mahmut
dc.date.accessioned2022-03-10T17:52:13Z
dc.date.accessioned2026-01-11T09:15:20Z
dc.date.available2022-03-10T17:52:13Z
dc.date.issued2013
dc.identifier.doidoiWOS:000339624904137
dc.identifier.eissn1556-1380
dc.identifier.issn1556-0864
dc.identifier.urihttps://hdl.handle.net/11424/221563
dc.identifier.wosWOS:000339624904137
dc.language.isoeng
dc.publisherLIPPINCOTT WILLIAMS & WILKINS
dc.relation.ispartofJOURNAL OF THORACIC ONCOLOGY
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectprognostic factors
dc.subjectsurvival
dc.subjectnon-small cell lung cancer
dc.subjectsecond line treatment
dc.titleIS SECOND LINE SYSTEMIC CHEMOTHERAPY BENEFICIAL IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC)? : A MULTICENTER DATA EVALUATION OF ANATOLIAN SOCIETY OF MEDICAL ONCOLOGY (ASMO)
dc.typeconferenceObject
dc.type.submeetingabstract
dspace.entity.typePublication
oaire.citation.endPageS876
oaire.citation.startPageS876
oaire.citation.titleJOURNAL OF THORACIC ONCOLOGY
oaire.citation.volume8

Files

Collections

Araştırma Çıktıları